NEWSROOM | Galderma

“A product for any type of skin”: celebrating Cetaphil’s range and reliability

Alastin Skincare: Galderma announces launch in the UK and direct distribution and expansion in Canada

Galderma announces progress with RelabotulinumtoxinA regulatory submissions

Galderma launches advanced new serum with ALASTIN Skincare® - C-RADICAL Defense Antioxidant Serum

Galderma’s World Eczema Week: driving change for the community

Powered by Peptides: Galderma introduces Cetaphil Healthy Renew, a retinol alternative skincare range

Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement

Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology

Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4

WCD 2023: Galderma to present extensive data demonstrating enduring commitment to delivering innovative solutions in dermatology

WCD 2023: Galderma’s scientific presentations

Galderma raises approximately USD 1 billion for newly issued shares in a private placement round

Galderma receives FDA approval for its newest hyaluronic acid filler, Restylane® Eyelight™